>>> Moulins' Carrefour stake crosses 10 percent threshold

Moulins' Carrefour stake crosses 10 percent threshold - RTRS

22-JUL-2015 17:37:18

PARIS, July 22 (Reuters) - Carrefour's CARR.PA biggest shareholder, the Moulin family, said on Wednesday it had raised its stake above 10 percent but had no plans to seek control of Europe's largest retailer.

The Moulins, who already have two board seats, said in a regulatory filing the Carrefour holding had risen to 10.06 percent from the 9.5 percent they owned in January, as a result of their decision to take a dividend payment in shares.

French market rules require investors to declare changes to their shareholdings whenever they cross any one of several key thresholds including 10 percent.

The family, which also owns France's Galeries Lafayette GALP.UL department stores, purchased an initial 6.1 percent Carrefour stake in April 2014.

Other Carrefour shareholders include Bernard Arnault, billionaire founder of luxury group LVMH LVMH.PA, who holds 8.99 percent; U.S. investment fund Colony Capital with 5.8 percent; and Brazilian tycoon Abilio Diniz, who owns 5.07 percent.

FT : Cairn Energy to vote against Vedanta offer

UK-based energy explorer Cairn Energy is set to vote against an offer to buy out minority shareholders in its former subsidiary Cairn India by Vedanta Ltd, according to people familiar with the situation.
The move will cast doubt on the overall transaction, which was proposed last month by Mumbai-based resources conglomerate Vedanta Ltd in part to bolster the finances of its heavily-indebted London-listed parent Vedanta Resources.

Cairn Energy is Cairn India’s largest minority shareholder, with a 10 per cent stake. Vedanta Resources controls about 60 per cent, but Indian law requires that a majority of minority shareholders also approve the deal.
This means that the two largest minorities — Cairn Energy and state-backed insurer Life Insurance Company of India (LIC), which holds about 9 per cent — are likely to be able to block the transaction, analysts say.
A vote against the merger would mark the latest twist in the often tumultuous relationship between Vedanta and Cairn, which began when Vedanta’s billionaire founder Anil Agarwal bought out the British group’s majority holding in a long-delayed $9.6bn deal in 2011.

Cairn Energy’s objections rest on “fundamental” disagreements over valuations, alongside a preference for holding an investment in an energy company rather than a distributed resources group, according to one person with direct knowledge of the matter.
Cairn Energy is also understood to have raised further concerns when it met representatives from Cairn India and Vedanta last month, including over the likely use of Cairn India’s Rs178bn ($2.8bn) net cash pile.
“There are big differences on valuation and worries about Vedanta’s debts, so the management are not minded to support it,” the person said, speaking on condition of anonymity. A spokesman for Cairn Energy declined to comment.
Some analysts suggest Vedanta Resources would use Cairn India’s cash pile to pay down a portion of its $8.5bn in net debts, diverting investment away from the Indian explorer’s main oilfields in the Indian state of Rajasthan.

Tom Albanese, Vedanta Resources chief executive, defended the deal, pledging to win over wavering minorities before it was put to a vote in the final quarter of 2015.
“There has been speculation about minority intentions, but there is a long time before we have to vote, and people will come round,” he said. “This transaction is still as compelling as it was a month or so ago.”
Vedanta argues Cairn India’s shareholders will benefit from being part of a diversified resources group with interests including iron ore, zinc and copper offering protection against swings in oil prices.
Falling commodity prices over recent weeks have sent Vedanta Ltd’s shares down 22 per cent during July, hitting the terms of the deal. This involves a share swap between the two companies and implied a 7 per cent premium to Cairn India’s share price on June 12.
LIC declined to comment on its stance, but Shriram Subramanian of Bangalore-based corporate governance research group InGovern said the Indian insurer was also likely to have “reservations” about the deal.
“Of course you expect minorities to ask for more at this stage,” Mr Subramanian said. “But we feel even improved terms aren’t likely to be good enough and in the end they [LIC] should oppose this, and it won’t go through.”

FT : Credit Suisse CEO crafts expansion plans

Credit Suisse's new chief executive has sounded out its main investors about plans to expand the Swiss bank's asset management operations, potentially through an acquisition, according to people familiar with the talks.

Tidjane Thiam, who took over at Switzerland's second-biggest bank on July 1, has met many of its top 20 investors in the past few weeks and discussed bulking up the asset management business while also signalling that acquisitions are a possibility, writes banking editor Martin Arnold.

As the bank prepares to unveil quarterly results on Thursday, the news that Mr Thiam is already eyeing potential takeovers will revive memories of his abortive bid for AIG's Asian unit only months after becoming CEO of UK insurer Prudential in 2009.

Most analysts expect Mr Thiam to slash underperforming parts of Credit Suisse's investment bank and expand its private banking operation, particularly in Asia. But he has signalled to investors that he sees most potential to expand in asset management, which is less capital intensive than investment banking and has strong cross-selling potential with Credit Suisse's private bank.

One possibility is for Credit Suisse to use a potential acquisition as a reason for raising capital from shareholders, which could also help to strengthen its capital levels, according to a person familiar with the situation. Mr Thiam is expected to unveil his new strategy in November, investors said. The bank declined to comment.

>>> US Gapping down

Gapping down
In reaction to disappointing earnings/guidance
: SCL -10%, ANGI -9.6%, ANGI -9.6%, ILMN -9.1%, LLTC -7.5%, EXPO -7.1%, AAPL -6.8%, TUP -6%, ARMH -4.8%, BEAV -4.1%, MSFT -3.6%, YHOO -2.3%, STJ -2.3%, PII -1.9%, EMC -1.5%, ABT -1%

M&A news: T -0.5%

Select metals/mining stocks trading lower: HL -3.6%, MT -3.1%, RIO -2.5%, GOLD -1.8%

Select oil/gas related names showing early weakness: SDRL -2.2%, RDS.A -1.8%, STO -1.5%, CHK -1.5%, TOT -1.4%

Other news: XOMA -68.2% (announces Phase 3 EYEGUARD-B Study did not meet the primary endpoint of time to first acute ocular exacerbation), IDI -18.8% (40%+ decline yesterday on cautious blog comments), ARRY -15.2% (AstraZeneca provides update on Selumetinib in uveal melanoma; did not meet its primary endpoint of progression free survival), VDSI -9.3% ( discloses it recently become aware that certain of its products which were sold by a VASCO European subsidiary to a third-party distributor may have been resold by the distributor to parties in Iran; sales may be in violation of U.S. economic sanctions), NVGN -8.7% (announces the resignation of CEO Dr Graham Kelly), RDUS -8.5% ( discloses that the FDA denied its re-request for breakthrough therapy designation for abaloparatide-SC, including the 18-month top-line results of its ACTIVE trial; announces a registered public offering of up to $250 million of its common stock), SWKS -5.9% (following AAPL results), EXEL -5.8% ( to offer 20 mln shares of its common stock ), CRUS -5.7% (in symp with AAPL), FXCM -5.4% (Board approved a 1-for-10 reverse split), FCSC -2.1% (commenced a public offering of common stock; size and price not disclosed), RGLS -4.9% (still checking), NXPI -4.8% (following AAPL results), BIIB -4.4% (disappointing Phase 1b data for 6 mg dose of aducanumab), AVGO -4.1% (following AAPL results), BHP -3.7% (reports FY15 gold production), STM -3.1% (in symp with AAPL), INVN -2.9% (following AAPL results), FIT -2.7% (cont vol post IPO), TSLA -1.8% (trading lower with the mkt), LLY -1.8% (announces results regarding solanezumab, that indicated the preservation of treatment effect in patients with mild Alzheimer's disease who received the drug early), FCSC -1.7% (commences a public offering of common stock), FB -1.6% (trading lower with the mkt),TWTR -1.2% (trading lower with the mkt), MU -1.1% (in symp with AAPL), DVAX -1% ( announces a public offering of common stock)

Analyst comments: BTU -5.8% (downgraded to Neutral from Overweight at JP Morgan), SD -3.8% (assumed with an Underperform at Credit Suisse), STM -3.1% (downgraded to Neutral at Citigroup), ALV -1.9% (downgraded to Neutral from Buy at BofA/Merrill ), AINV -1.7% (downgraded to Equal Weight from Overweight at Barclays ), CHK -1.5% (downgraded to Neutral from Outperform at Credit Suisse), EBAY -1% (downgraded to Mkt Perform from Outperform at Raymond James)

>>> US Gapping up

Gapping up
In reaction to strong earnings/guidance
: ISRG +12.3%, THOR +9%, TMO +7%, CX +4.5%, CHKP +4.4%, WHR +4.4%, HAWK +4.3%, ITW +4.2%, NUAN +4.1%, PKG +3.7%, VASC +2.8%, MANH +2.2%, CMG +2.1%, OC +1.9%, IBKR +1.2%, BABY +1.2%, BABY +1.2%, ACE +1.1%, KO +0.9%, NYLD +0.8%

M&A news: THOR +8.7% (to be acquired by St. Jude Medical (STJ) for $63.50 per share), GNW +2.9% (in negotiations with AXA (AXAHY) after receiving an irrevocable offer to purchase its lifestyle protection insurance business), DTV +0.8% (WSJ reporting FCC expected to approve T / DTV deal)

Other news: BLDP +4.6% (will provide a 1 MW ClearGen fuel cell distributed generation system for Hydrogène de France, to be deployed at an AkzoNobel (AKZOY) sodium chlorate chemical plant), PRKR +3.5% (Parkervision and RFMW sign worldwide distribution agreement for ParkerVision products and services ), STAY +3.5% (appoints Gerardo Lopez as CEO, effective August 24, 2015), ADK +3.1% (discloses entry into separate At Market Issuance Sales Agreements to sell up to 800k shares of its 10.875% Series A Cumulative Redeemable Preferred Stock), GLNG +2% (executed agreements for conversion of the 126,000 m(3) LNG carrier Gandria to a Golar floating liquefaction facility), INFY +1.3% (cont strength)

Analyst comments
: XOM +0.5% (added to Conviction Buy List at Goldman)

(BI) Biogen Alzheimer's Drug Fails to Deliver on Key Lower Dose

--> See all Alzheimer names under pressure, ROG Underperforming


Biogen Alzheimer's Drug Fails to Deliver on Key Lower Dose
2015-07-22 12:49:42.12 GMT

BI BIOT GLOB SBKEYS
The 6-milligram dose of Biogen's Alzheimer's drug aducanumab
(BIIB037) failed to show statistically significant benefit in
cognitive function in its PRIME study at 54 weeks, tempering
expectations for its potential. The 10-mg dose showed
significant improvement in 1Q, but a high incidence of
toxicities such as brain swelling (ARIA) caused concern. The
6-mg dose was viewed potentially as a trade-off in risk, yet
results released July 22 call into question whether it will have
a sufficient benefit in a larger study.

|0|0|553534|200960877|NOT_APPLICABLE|NOT_APPLICABLE|

This research note has been published by Bloomberg Intelligence.
For more information, see BI <GO>
-0- Jul/22/2015 12:49 GMT

>>> Billionaire Pinault Family Said to Near Ponant Luxury Ships Deal


Billionaire Pinault Family Said to Near Ponant Luxury Ships Deal

Artemis SA, the holding company of France’s billionaire Pinault family, is in advanced talks to buy luxury cruise-ship operator Ponant from buyout firm Bridgepoint, according to people familiar with the situation.

The talks between Artemis and Bridgepoint are exclusive, said two of the people, who asked not to be identified because the negotiations are private. Ponant may have an equity value of about 400 million euros ($438 million) and a deal could be announced by the end of this month, said another person.

A deal would hand Francois Pinault and his family another luxury lifestyle company, adding to assets such as auction house Christie’s and Bordeaux first-growth wine estate Chateau Latour. Artemis also controls Kering SA with its fashion brands such as Gucci and Saint Laurent. Pinault’s son, Francois-Henri, is chairman of Artemis and Kering.

Bridgepoint acquired Ponant from French shipping group CMA CGM in 2012 for an undisclosed amount. The yacht operator had 120 million euros in revenue last year, according to its website. Founded in 1988, Ponant operates a fleet of yachts that carried 23,000 passengers last year.

Representatives for Artemis and Bridgepoint declined to comment on a potential deal when contacted by Bloomberg.